PMC:7212965 / 34674-35017 JSONTXT

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T157","span":{"begin":151,"end":159},"obj":"Disease"},{"id":"T158","span":{"begin":220,"end":228},"obj":"Disease"}],"attributes":[{"id":"A157","pred":"mondo_id","subj":"T157","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A158","pred":"mondo_id","subj":"T158","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"n baseline LFTs at the time of admission and consider LFT monitoring throughout the hospitalization, particularly in the context of drug treatment for COVID-19.\n7. In hospitalized patients undergoing drug treatment for COVID-19, evaluate for treatment-related Gl and hepatic adverse effects.\nAbnormal LFTs were reported in approximately 15% o"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T52","span":{"begin":132,"end":136},"obj":"Chemical"},{"id":"T53","span":{"begin":201,"end":205},"obj":"Chemical"}],"attributes":[{"id":"A52","pred":"chebi_id","subj":"T52","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A53","pred":"chebi_id","subj":"T53","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"}],"text":"n baseline LFTs at the time of admission and consider LFT monitoring throughout the hospitalization, particularly in the context of drug treatment for COVID-19.\n7. In hospitalized patients undergoing drug treatment for COVID-19, evaluate for treatment-related Gl and hepatic adverse effects.\nAbnormal LFTs were reported in approximately 15% o"}

{"project":"LitCovid-sentences","denotations":[{"id":"T221","span":{"begin":161,"end":163},"obj":"Sentence"},{"id":"T222","span":{"begin":165,"end":292},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"n baseline LFTs at the time of admission and consider LFT monitoring throughout the hospitalization, particularly in the context of drug treatment for COVID-19.\n7. In hospitalized patients undergoing drug treatment for COVID-19, evaluate for treatment-related Gl and hepatic adverse effects.\nAbnormal LFTs were reported in approximately 15% o"}

{"project":"LitCovid-PubTator","denotations":[{"id":"849","span":{"begin":151,"end":159},"obj":"Disease"},{"id":"852","span":{"begin":181,"end":189},"obj":"Species"},{"id":"853","span":{"begin":220,"end":228},"obj":"Disease"},{"id":"899","span":{"begin":293,"end":306},"obj":"Disease"}],"attributes":[{"id":"A849","pred":"tao:has_database_id","subj":"849","obj":"MESH:C000657245"},{"id":"A852","pred":"tao:has_database_id","subj":"852","obj":"Tax:9606"},{"id":"A853","pred":"tao:has_database_id","subj":"853","obj":"MESH:C000657245"},{"id":"A899","pred":"tao:has_database_id","subj":"899","obj":"MESH:D018376"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"n baseline LFTs at the time of admission and consider LFT monitoring throughout the hospitalization, particularly in the context of drug treatment for COVID-19.\n7. In hospitalized patients undergoing drug treatment for COVID-19, evaluate for treatment-related Gl and hepatic adverse effects.\nAbnormal LFTs were reported in approximately 15% o"}